A research programme aimed at improving the suspected head and neck cancer pathway, speeding up diagnosis, improving the patient experience and optimising the use of healthcare resources.

The head and neck cancer pathway

Suspected head and neck cancer is the fifth largest group of suspected cancer referrals seen by hospitals


EVEREST-HN involves collaborations with researchers from across the UK, based in numerous NHS institutions and 7 UK universities.

Professor Paleri_0

EVEREST-HN is funded by the National Institute for Health Research (NIHR) PGfAR stream and the International Centre for Recurrent Head and Neck Cancer (IReC), which is funded by The Royal Marsden Cancer Charity.

Key dates

The EVEREST-HN trial will open in October 2022. The main trial will start recruiting patients in late 2025. Results are due in 2029.

Launch event

In September 2022, a launch event for EVEREST-HN took place, focusing on: the EVEREST-HN work package plans; sharing the patient experience of the suspected head and neck cancer pathway; and outlining the opportunities for PIs and Associate PIs in EVEREST-HN.

Contact us

Find us on Twitter: search EVEREST_HN